<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/89BD5E8F-7B26-4C2F-A710-9970A0D54778/chart/price-vs-fair-value?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/89BD5E8F-7B26-4C2F-A710-9970A0D54778/chart/price-vs-fair-value"/></p>
<p>纳斯达克：BRKR 1 年股价与公允价值</p>
<p>探索来自社区的 Bruker 公允价值并选择您的观点</p>
<p><strong>Bruker Corporation</strong>（纳斯达克：BRKR）的股价在过去一个月表现非常糟糕，下降了 31%。最近的下跌使得股东在过去一年中遭遇了 51% 的损失，真是灾难性的结果。</p>
<p>尽管其股价大幅下跌，但考虑到美国生命科学行业几乎一半的公司市销率（&#34;P/S&#34;）超过 3.5 倍，甚至超过 6 倍的市销率也并不罕见，Bruker 目前可能仍然看起来是一个强有力的买入机会，其市销率为 1.3 倍。然而，市销率可能较低是有原因的，需要进一步调查以确定是否合理。</p>
<p>特朗普承诺要&#34;释放&#34;美国的石油和天然气，这 15 只美国股票的发展有望受益。</p>
<p>查看我们对 Bruker 的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/527317-ps-multiple-vs-industry-1-dark-2/1754836775472?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/527317-ps-multiple-vs-industry-1-dark-2/1754836775472"/></p>
<p>纳斯达克：BRKR 市销率与行业比较 2025 年 8 月 10 日</p>
<h3>Bruker 最近的表现如何？</h3>
<p>Bruker 最近确实表现不错，因为其收入增长超过了大多数其他公司。可能许多人预计强劲的收入表现将大幅下降，这抑制了股价，因此市销率也随之下降。如果不是这样，那么现有股东对未来股价的方向有理由感到相当乐观。</p>
<p>想知道分析师如何看待 Bruker 的未来与行业的比较吗？那么，我们的 <strong>免费</strong> 报告是一个很好的起点。</p>
<h2>收入增长指标告诉我们关于低市销率的什么？</h2>
<p>为了证明其市销率的合理性，Bruker 需要实现显著低于行业的微弱增长。</p>
<p>回顾过去，我们看到公司去年成功实现了 10% 的收入增长。令人欣慰的是，收入在三年前的基础上总共增长了 39%，部分得益于过去 12 个月的增长。因此，股东们肯定会欢迎这些中期收入增长率。</p>
<p>展望未来，覆盖该公司的 11 位分析师的估计显示，未来三年收入预计将每年增长 3.2%。与此同时，行业的其他部分预计每年将增长 6.8%，这显然更具吸引力。</p>
<p>根据这些信息，我们可以看到为什么 Bruker 的市销率低于行业。似乎大多数投资者预计未来增长有限，因此只愿意为该股票支付较低的价格。</p>
<h2>Bruker 的市销率对投资者意味着什么？</h2>
<p>Bruker 的股价暴跌，其市销率也随之下降。虽然市销率不应成为您是否购买股票的决定性因素，但它是收入预期的一个相当有效的晴雨表。</p>
<p>我们已经确定，Bruker 维持其低市销率是因为其预测增长低于更广泛的行业，正如预期的那样。现在，股东们接受低市销率，因为他们承认未来的收入可能不会带来任何令人愉快的惊喜。除非这些条件改善，否则它们将继续在这些水平上形成股价的障碍。</p>
<p>此外，您还应该了解我们发现的 <strong>Bruker 的 3 个警告信号</strong>（其中 1 个是无法忽视的）。</p>
<p>如果您对 Bruker 的业务实力 <strong>不确定</strong>，为什么不探索我们互动的股票列表，寻找一些您可能错过的具有良好商业基础的其他公司呢？</p>

布鲁克

<p>布鲁克公司（NASDAQ:BRKR）的股价在过去一个月下跌了 31%，导致股东在过去一年中损失了 51%。尽管出现了这种下滑，其市销率（P/S）为 1.3 倍，仍然表明与行业同行相比，可能仍然是一个买入机会。然而，分析师预测布鲁克的收入增长将落后于行业，预计年增长率仅为 3.2%，而行业的年增长率为 6.8%。这种对未来增长有限的预期反映在低市销率上，表明股价可能面临潜在障碍</p>

<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/89BD5E8F-7B26-4C2F-A710-9970A0D54778/chart/price-vs-fair-value" alt="" original-src="https://images.simplywall.st/company/89BD5E8F-7B26-4C2F-A710-9970A0D54778/chart/price-vs-fair-value"/></p>
<p>NasdaqGS:BRKR 1 Year Share Price vs Fair Value</p>
<div class="lb-trans"><p>纳斯达克：BRKR 1 年股价与公允价值</p>
</div><p>Explore Bruker's Fair Values from the Community and select yours</p>
<div class="lb-trans"><p>探索来自社区的 Bruker 公允价值并选择您的观点</p>
</div><p>The <strong>Bruker Corporation</strong> (NASDAQ:BRKR) share price has fared very poorly over the last month, falling by a substantial 31%. The recent drop completes a disastrous twelve months for shareholders, who are sitting on a 51% loss during that time.</p>
<div class="lb-trans"><p><strong>Bruker Corporation</strong>（纳斯达克：BRKR）的股价在过去一个月表现非常糟糕，下降了 31%。最近的下跌使得股东在过去一年中遭遇了 51% 的损失，真是灾难性的结果。</p>
</div><p>Although its price has dipped substantially, Bruker may still look like a strong buying opportunity at present with its price-to-sales (or &#34;P/S&#34;) ratio of 1.3x, considering almost half of all companies in the Life Sciences industry in the United States have P/S ratios greater than 3.5x and even P/S higher than 6x aren't out of the ordinary. However, the P/S might be quite low for a reason and it requires further investigation to determine if it's justified.</p>
<div class="lb-trans"><p>尽管其股价大幅下跌，但考虑到美国生命科学行业几乎一半的公司市销率（&#34;P/S&#34;）超过 3.5 倍，甚至超过 6 倍的市销率也并不罕见，Bruker 目前可能仍然看起来是一个强有力的买入机会，其市销率为 1.3 倍。然而，市销率可能较低是有原因的，需要进一步调查以确定是否合理。</p>
</div><p>Trump has pledged to &#34;unleash&#34; American oil and gas and these 15 US stocks have developments that are poised to benefit.</p>
<div class="lb-trans"><p>特朗普承诺要&#34;释放&#34;美国的石油和天然气，这 15 只美国股票的发展有望受益。</p>
</div><p>View our latest analysis for Bruker</p>
<div class="lb-trans"><p>查看我们对 Bruker 的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/527317-ps-multiple-vs-industry-1-dark-2/1754836775472" alt="" original-src="https://images.simplywall.st/asset/chart/527317-ps-multiple-vs-industry-1-dark-2/1754836775472"/></p>
<p>NasdaqGS:BRKR Price to Sales Ratio vs Industry August 10th 2025</p>
<div class="lb-trans"><p>纳斯达克：BRKR 市销率与行业比较 2025 年 8 月 10 日</p>
</div><h3>How Has Bruker Performed Recently?</h3>
<div class="lb-trans"><h3>Bruker 最近的表现如何？</h3>
</div><p>Bruker certainly has been doing a good job lately as it's been growing revenue more than most other companies. It might be that many expect the strong revenue performance to degrade substantially, which has repressed the share price, and thus the P/S ratio. If not, then existing shareholders have reason to be quite optimistic about the future direction of the share price.</p>
<div class="lb-trans"><p>Bruker 最近确实表现不错，因为其收入增长超过了大多数其他公司。可能许多人预计强劲的收入表现将大幅下降，这抑制了股价，因此市销率也随之下降。如果不是这样，那么现有股东对未来股价的方向有理由感到相当乐观。</p>
</div><p>Keen to find out how analysts think Bruker's future stacks up against the industry? In that case, our <strong>free</strong> report is a great place to start.</p>
<div class="lb-trans"><p>想知道分析师如何看待 Bruker 的未来与行业的比较吗？那么，我们的 <strong>免费</strong> 报告是一个很好的起点。</p>
</div><h2>What Are Revenue Growth Metrics Telling Us About The Low P/S?</h2>
<div class="lb-trans"><h2>收入增长指标告诉我们关于低市销率的什么？</h2>
</div><p>In order to justify its P/S ratio, Bruker would need to produce anemic growth that's substantially trailing the industry.</p>
<div class="lb-trans"><p>为了证明其市销率的合理性，Bruker 需要实现显著低于行业的微弱增长。</p>
</div><p>Taking a look back first, we see that the company managed to grow revenues by a handy 10% last year. Pleasingly, revenue has also lifted 39% in aggregate from three years ago, partly thanks to the last 12 months of growth. Accordingly, shareholders would have definitely welcomed those medium-term rates of revenue growth.</p>
<div class="lb-trans"><p>回顾过去，我们看到公司去年成功实现了 10% 的收入增长。令人欣慰的是，收入在三年前的基础上总共增长了 39%，部分得益于过去 12 个月的增长。因此，股东们肯定会欢迎这些中期收入增长率。</p>
</div><p>Shifting to the future, estimates from the eleven analysts covering the company suggest revenue should grow by 3.2% per year over the next three years. Meanwhile, the rest of the industry is forecast to expand by 6.8% per year, which is noticeably more attractive.</p>
<div class="lb-trans"><p>展望未来，覆盖该公司的 11 位分析师的估计显示，未来三年收入预计将每年增长 3.2%。与此同时，行业的其他部分预计每年将增长 6.8%，这显然更具吸引力。</p>
</div><p>With this information, we can see why Bruker is trading at a P/S lower than the industry. It seems most investors are expecting to see limited future growth and are only willing to pay a reduced amount for the stock.</p>
<div class="lb-trans"><p>根据这些信息，我们可以看到为什么 Bruker 的市销率低于行业。似乎大多数投资者预计未来增长有限，因此只愿意为该股票支付较低的价格。</p>
</div><h2>What Does Bruker's P/S Mean For Investors?</h2>
<div class="lb-trans"><h2>Bruker 的市销率对投资者意味着什么？</h2>
</div><p>Shares in Bruker have plummeted and its P/S has followed suit. While the price-to-sales ratio shouldn't be the defining factor in whether you buy a stock or not, it's quite a capable barometer of revenue expectations.</p>
<div class="lb-trans"><p>Bruker 的股价暴跌，其市销率也随之下降。虽然市销率不应成为您是否购买股票的决定性因素，但它是收入预期的一个相当有效的晴雨表。</p>
</div><p>We've established that Bruker maintains its low P/S on the weakness of its forecast growth being lower than the wider industry, as expected. Right now shareholders are accepting the low P/S as they concede future revenue probably won't provide any pleasant surprises. Unless these conditions improve, they will continue to form a barrier for the share price around these levels.</p>
<div class="lb-trans"><p>我们已经确定，Bruker 维持其低市销率是因为其预测增长低于更广泛的行业，正如预期的那样。现在，股东们接受低市销率，因为他们承认未来的收入可能不会带来任何令人愉快的惊喜。除非这些条件改善，否则它们将继续在这些水平上形成股价的障碍。</p>
</div><p>Plus, you should also learn about these <strong>3 warning signs we've spotted with Bruker</strong> (including 1 which can't be ignored).</p>
<div class="lb-trans"><p>此外，您还应该了解我们发现的 <strong>Bruker 的 3 个警告信号</strong>（其中 1 个是无法忽视的）。</p>
</div><p>If you're <strong>unsure about the strength of Bruker's business</strong>, why not explore our interactive list of stocks with solid business fundamentals for some other companies you may have missed.</p>
<div class="lb-trans"><p>如果您对 Bruker 的业务实力 <strong>不确定</strong>，为什么不探索我们互动的股票列表，寻找一些您可能错过的具有良好商业基础的其他公司呢？</p>
</div>

为什么布鲁克公司（NASDAQ:BRKR）股价暴跌 31% 不应令投资者感到意外